Introduction: A Saturday Run That Taught Me About Risk
I still remember a Saturday morning in 2017 when a delivery truck arrived late with a pallet of tubing and I had to decide whether to put it into clinical use that afternoon. In our chemistry testing laboratory the clock was ticking and the clinical team wanted an answer fast. I have over 15 years working across device chemistry and regulatory testing, and moments like that sharpened my sense of urgency (and patience) — you learn quickly what matters. The data we had then showed 3 out of 20 lots with odd peaks on a routine screen. Could those peaks become leachables under real use? Could they cause patient harm?
That situation became the seed for my focus on robust compatibility assessment. I will share how I approached similar puzzles in Manila and Cebu, including a concrete incident in October 2018 where solvent extraction of PVC catheter lot 0423 returned unexpected semi-volatile components on an Agilent 7890B GC with 5977 MSD. These are not abstract risks — they have time, cost, and regulatory consequences. So, do compatibility studies really catch the bad actors before deployment? Let’s look closer and see where conventional practice helps and where it misses the mark.
Deeper Layer: Why Traditional Approaches Miss Key Risks
Why do conventional studies fall short?
Early in my career I relied on a standard medical device compatibility study template the same way many teams do: extractables profiling, a simple leachables challenge, then a cytotoxicity screen. On paper it looked complete. In practice, two technical weaknesses kept surfacing. First, extraction conditions often do not mimic the real-use energy inputs — temperature, dynamic flow, and repeated stress cycles. Second, analytical windows can be too narrow; using a single GC-MS run without complementary HPLC-MS analyses leaves polar and non-volatile species unseen. The result: blind spots.
To give you a concrete example, in November 2019 we ran parallel tests on a silicone catheter. Under accelerated ethanol extraction we saw three prominent peaks. But when we ran an HPLC-MS and a targeted ionic assay, two additional polar species above 5 ppm were detected. That oversight would have been non-trivial for a 510(k) submission. I firmly believe that relying on one extraction solvent or one detector invites regulatory and clinical setbacks. The methods sound thorough, but the details — solvent choice, contact time, analytical method — matter in ways that are easy to underestimate. I say this from direct experience: I’ve had to rework protocols after a single missed leachable delayed a product launch by six months.
Forward-Looking Principles: New Tech and Practical Steps
What’s Next for Compatibility Testing?
Looking ahead, I focus on principles rather than rigid checklists. First, mimic-use conditions early: thermal cycling, flow shear, and real contact media (saline, blood simulant, lipophilic agents). Second, broaden analytical coverage — combine GC-MS, HPLC-MS/MS, and targeted ion chromatography as needed. Third, use risk-based thresholds tied to exposure. For example, when we evaluated a drug-delivery port in 2021, we set a conservative 1–2 ppm action level for genotoxic species based on intended use and found that approach prevented later rework. Adopting orthogonal techniques reduces false negatives — that’s not theoretical, I’ve seen it in three projects across two clinical partners in Metro Manila.
For teams adopting new workflows, consider small pilot runs that simulate 30 days of use compressed into a week. It speeds learning and surfaces failure modes early. And yes — you will encounter surprises; one of our pilots produced a nitrosamine trace only after repeated ethanol rinses — an odd result, but informative. Use that data to refine solvents and contact durations. Also, integrate extractables testing early in the design cycle to avoid late-stage surprises. The link between material science and analytical strategy is where you earn time and money back.
To evaluate options, I recommend three clear metrics: sensitivity of the analytical suite (limit of detection in ppm), realism of extraction conditions (do they reflect use-case temperature and medium?), and traceability of method validation (are calibrations and reference standards documented?). If you score candidate labs or methods against those metrics, you can make a defensible choice. I’ve walked small med-tech teams through this scoring in workshops since 2016 — it reduces surprises and aligns the R&D, QC, and regulatory teams. — when you get it right, approvals move smoother. For trusted medical device testing partnerships, consider engaging teams with practical bench experience like mine and partners such as Wuxi AppTec Medical device testing